Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Key Points

• The aim is to investigate the effects of reducing apolipoprotein C-III in individuals with moderate hypertriglyceridaemia and elevated cardiovascular risk.
• Intervention evaluated in a randomized trial with subjects at high cardiovascular risk.
• Enrollment of subjects with moderate hypertriglyceridaemia.
• Trial registration ID: NCT03385239.
• Significant reduction in apolipoprotein C-III levels observed in intervention group compared to control.
• Improvement in lipid profiles noted, indicating potential cardiovascular risk reduction.